Trial Outcomes & Findings for Evaluating Cancer Survivorship Care Models (NCT NCT02362750)

Last Updated: 2026-03-25

Results Overview

Patient-reported quality of care was measured using the Survivorship Care Quality Index, which consists of 9 factors and a total of 46 metrics. The factors are then grouped into domains. Domain 1, Informed and grounded patients, consist of 2 factors: 1) delivering mental health and social support, and 2) providing information and resources on the expectations of survivorship care. Domain 2, the patient-provider alliance, consists of 3 factors: 1) feeling empowered to engage in their care, 2) having supportive and respectful clinicians, and 3) having meaningful communication between the patient and clinician. Domain 3, a supportive health and wellness system, consists of 5 factors: 1) coordinating care across providers, 2) preparing patients for transitions in care, 3) having access to a full spectrum of care, 4) providing practical life support, and 5) making sure patients belong to a medical home during this phase of their care.

Recruitment status

COMPLETED

Target enrollment

991 participants

Primary outcome timeframe

Patients complete a survey within one week after their survivorship visit, and 6 months post visit.

Results posted on

2026-03-25

Participant Flow

3 models of survivorship care were identified from the environmental scan of Commission on Cancer-accredited institutions. "High performing institutions" (in quality of care) were recruited from the Assoc, of Community Cancer Centers' and GW Cancer Institute's listservs across the three models model. Institutions recruited participants from their own survivorship care programs. 991 survivors were enrolled at baseline.

Participant milestones

Participant milestones
Measure	Cancer Survivors in Consultative Specialized Survivorship Clinics Cancer Survivors receiving follow-up care in Consultative Specialized Survivorship Clinic Models. Data collected at (1): Pre-Visit Baseline (2): 1 Week Post-Visit (3): 3 Months Post-Visit (4): 6 Months Post-Visit.	Cancer Survivors in Longitudinal Specialized Survivorship Clinics Cancer Survivors receiving follow-up care in Longitudinal Specialized Survivorship Clinic Models. Data collected at (1): Pre-Visit Baseline (2): 1 Week Post-Visit (3): 3 Months Post-Visit (4): 6 Months Post-Visit.	Cancer Survivors in Oncology Embedded Survivorship Care Clinics Cancer Survivors receiving follow-up care in Oncology Embedded Survivorship Care Models. Data collected at (1): Pre-Visit Baseline (2): 1 Week Post-Visit (3): 3 Months Post-Visit (4): 6 Months Post-Visit.
Baseline prior to survivorship visit STARTED	412	205	374
Baseline prior to survivorship visit COMPLETED	412	205	374
Baseline prior to survivorship visit NOT COMPLETED	0	0	0
Within 1 week post survivorship visit STARTED	412	205	374
Within 1 week post survivorship visit COMPLETED	393	187	346
Within 1 week post survivorship visit NOT COMPLETED	19	18	28
3 months post survivorship visit STARTED	393	187	346
3 months post survivorship visit COMPLETED	365	175	328
3 months post survivorship visit NOT COMPLETED	28	12	18
6 months post survivorship visit STARTED	365	175	328
6 months post survivorship visit COMPLETED	323	159	295
6 months post survivorship visit NOT COMPLETED	42	16	33

Reasons for withdrawal

Reasons for withdrawal
Measure	Cancer Survivors in Consultative Specialized Survivorship Clinics Cancer Survivors receiving follow-up care in Consultative Specialized Survivorship Clinic Models. Data collected at (1): Pre-Visit Baseline (2): 1 Week Post-Visit (3): 3 Months Post-Visit (4): 6 Months Post-Visit.	Cancer Survivors in Longitudinal Specialized Survivorship Clinics Cancer Survivors receiving follow-up care in Longitudinal Specialized Survivorship Clinic Models. Data collected at (1): Pre-Visit Baseline (2): 1 Week Post-Visit (3): 3 Months Post-Visit (4): 6 Months Post-Visit.	Cancer Survivors in Oncology Embedded Survivorship Care Clinics Cancer Survivors receiving follow-up care in Oncology Embedded Survivorship Care Models. Data collected at (1): Pre-Visit Baseline (2): 1 Week Post-Visit (3): 3 Months Post-Visit (4): 6 Months Post-Visit.
Within 1 week post survivorship visit Lost to Follow-up	19	18	28
3 months post survivorship visit Lost to Follow-up	28	12	18
6 months post survivorship visit Lost to Follow-up	42	16	33

Baseline Characteristics

Evaluating Cancer Survivorship Care Models

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Consultative Specialized Survivorship Clinic Patients n=412 Participants Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions complete four surveys (Survivor Survey (1): Pre-Visit Baseline (2): 1 Week Post-Visit (3): 3 Months Post-Visit (4): 6 Months Post-Visit) regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization. Survivors obtain survivorship care that is organized in a specialized consultative model. In a single, consultative visit that dedicated specifically to survivorship the majority of Tier 1 Essential Elements, including the survivorship care plan (SCP), psychosocial care, health promotion services and symptom management, are provided through direct access during the visit. This model is typically led by a nurse practitioner (NP) or physician's assistant (PA) with specialized training.	Longitudinal Specialized Survivorship Clinic Patients n=205 Participants Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions complete four surveys (Survivor Survey (1): Pre-Visit Baseline (2): 1 Week Post-Visit (3): 3 Months Post-Visit (4): 6 Months Post-Visit) regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization. Survivors obtain survivorship care that is organized in a specialized longitudinal model. In a series of survivorship-specific visits scheduled at predetermined intervals and as needed by the patient, the majority of Tier 1 essential elements are provided through direct access onsite rather than through a referral, including the SCP, surveillance for impacts of treatment, screenings for new cancers/recurrences, health promotion education, psychosocial care and symptom management. This model is typically led by an NP or a PA.	Oncology Embedded Model n=374 Participants Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions complete four surveys ((1): Pre-Visit Baseline (2): 1 Week Post-Visit (3): 3 Months Post-Visit (4): 6 Months Post-Visit) regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization. Survivorship care is organized in an oncology embedded model, where care is part of standard post-treatment oncology follow-up care. How care is scheduled varies by institution, but is provided in a longitudinal model. Unlike in the Specialized Longitudinal Model, survivorship care is not always provided systematically, and may be on an as needed basis at the request of the patient. Providers likely use referrals to deliver some of the key survivorship services than either of the other two models. This model is typically provided by the treating oncologist, often with support from an NP/PA, patient na	Total n=991 Participants Total of all reporting groups
Age, Continuous	59.2 years STANDARD_DEVIATION 11.7 • n=138 Participants	59.7 years STANDARD_DEVIATION 12.1 • n=62 Participants	61.8 years STANDARD_DEVIATION 11.1 • n=123 Participants	60.3 years STANDARD_DEVIATION 11.6 • n=158 Participants
Sex/Gender, Customized Female	354 Participants n=138 Participants	198 Participants n=62 Participants	305 Participants n=123 Participants	857 Participants n=158 Participants
Sex/Gender, Customized male	57 Participants n=138 Participants	7 Participants n=62 Participants	69 Participants n=123 Participants	133 Participants n=158 Participants
Sex/Gender, Customized Missing	1 Participants n=138 Participants	0 Participants n=62 Participants	0 Participants n=123 Participants	1 Participants n=158 Participants
Race/Ethnicity, Customized White	332 Participants n=138 Participants	193 Participants n=62 Participants	313 Participants n=123 Participants	838 Participants n=158 Participants
Race/Ethnicity, Customized Black	46 Participants n=138 Participants	4 Participants n=62 Participants	34 Participants n=123 Participants	84 Participants n=158 Participants
Race/Ethnicity, Customized Other	30 Participants n=138 Participants	7 Participants n=62 Participants	21 Participants n=123 Participants	58 Participants n=158 Participants
Race/Ethnicity, Customized unknown/missing	4 Participants n=138 Participants	1 Participants n=62 Participants	6 Participants n=123 Participants	11 Participants n=158 Participants
Race/Ethnicity, Customized Ethnicity: Hispanic	11 Participants n=138 Participants	2 Participants n=62 Participants	12 Participants n=123 Participants	25 Participants n=158 Participants
Race/Ethnicity, Customized Ethnicity: Non-Hispanic	401 Participants n=138 Participants	203 Participants n=62 Participants	362 Participants n=123 Participants	966 Participants n=158 Participants
Cancer site Breast	341 participants n=138 Participants	195 participants n=62 Participants	295 participants n=123 Participants	831 participants n=158 Participants
Cancer site Prostate	48 participants n=138 Participants	4 participants n=62 Participants	60 participants n=123 Participants	112 participants n=158 Participants
Cancer site Colorectal	23 participants n=138 Participants	6 participants n=62 Participants	19 participants n=123 Participants	48 participants n=158 Participants
Education High school/GED grad or less	93 Participants n=138 Participants	51 Participants n=62 Participants	131 Participants n=123 Participants	275 Participants n=158 Participants
Education Some college/2-yr degree	127 Participants n=138 Participants	74 Participants n=62 Participants	126 Participants n=123 Participants	327 Participants n=158 Participants
Education 4-yr college grad	118 Participants n=138 Participants	51 Participants n=62 Participants	67 Participants n=123 Participants	236 Participants n=158 Participants
Education Grad school degree	74 Participants n=138 Participants	28 Participants n=62 Participants	47 Participants n=123 Participants	149 Participants n=158 Participants
Education Missing	0 Participants n=138 Participants	1 Participants n=62 Participants	3 Participants n=123 Participants	4 Participants n=158 Participants
Income <$25,000	78 participants n=138 Participants	25 participants n=62 Participants	75 participants n=123 Participants	178 participants n=158 Participants
Income <$25,000 -$74,999	147 participants n=138 Participants	109 participants n=62 Participants	163 participants n=123 Participants	419 participants n=158 Participants
Income $75,000+	145 participants n=138 Participants	57 participants n=62 Participants	94 participants n=123 Participants	296 participants n=158 Participants
Marital Status Married/Living with Partner	266 participants n=138 Participants	137 participants n=62 Participants	248 participants n=123 Participants	651 participants n=158 Participants
Marital Status Widowed	113 participants n=138 Participants	57 participants n=62 Participants	95 participants n=123 Participants	265 participants n=158 Participants
Marital Status Divorced/Separated	33 participants n=138 Participants	9 participants n=62 Participants	29 participants n=123 Participants	71 participants n=158 Participants
Employment Status Working (as paid employee)	197 Participants n=138 Participants	96 Participants n=62 Participants	149 Participants n=123 Participants	442 Participants n=158 Participants
Employment Status Self-Employed	43 Participants n=138 Participants	20 Participants n=62 Participants	50 Participants n=123 Participants	113 Participants n=158 Participants
Employment Status Not working (including retired and disabled)	171 Participants n=138 Participants	88 Participants n=62 Participants	175 Participants n=123 Participants	434 Participants n=158 Participants
Employment Status Missing	1 Participants n=138 Participants	1 Participants n=62 Participants	0 Participants n=123 Participants	2 Participants n=158 Participants
Stage of Cancer Diagnosis Stage 0 - cancer in situ; the cancer is still in the place it started	37 Participants n=138 Participants	11 Participants n=62 Participants	46 Participants n=123 Participants	94 Participants n=158 Participants
Stage of Cancer Diagnosis Stage 1 - cancer that has not grown deeply into nearby tissue	146 Participants n=138 Participants	78 Participants n=62 Participants	133 Participants n=123 Participants	357 Participants n=158 Participants
Recurrence or Diagnosis of New Cancer At 6 months	6 participants n=138 Participants	0 participants n=62 Participants	8 participants n=123 Participants	14 participants n=158 Participants
Stage of Cancer Diagnosis Stage 2 - cancer has grown deeply into nearby tissue	131 Participants n=138 Participants	66 Participants n=62 Participants	92 Participants n=123 Participants	289 Participants n=158 Participants
Stage of Cancer Diagnosis Stage 3 - cancer has grown deeply into nearby tissue and may have spread to lymph nodes	48 Participants n=138 Participants	20 Participants n=62 Participants	37 Participants n=123 Participants	105 Participants n=158 Participants
Stage of Cancer Diagnosis Stage 4 - cancer has metasticized and spread to other organs or parts of the body	5 Participants n=138 Participants	2 Participants n=62 Participants	4 Participants n=123 Participants	11 Participants n=158 Participants
Stage of Cancer Diagnosis Don't know	40 Participants n=138 Participants	25 Participants n=62 Participants	55 Participants n=123 Participants	120 Participants n=158 Participants
Stage of Cancer Diagnosis Missing	5 Participants n=138 Participants	3 Participants n=62 Participants	7 Participants n=123 Participants	15 Participants n=158 Participants
Treatments Completed Surgery	349 participants n=138 Participants	198 participants n=62 Participants	303 participants n=123 Participants	850 participants n=158 Participants
Treatments Completed Chemotherapy, target therapy or immunotherapy	202 participants n=138 Participants	94 participants n=62 Participants	138 participants n=123 Participants	434 participants n=158 Participants
Treatments Completed Radiation	325 participants n=138 Participants	139 participants n=62 Participants	315 participants n=123 Participants	779 participants n=158 Participants
Treatments Completed Other	9 participants n=138 Participants	13 participants n=62 Participants	11 participants n=123 Participants	33 participants n=158 Participants
Receiving Hormone Therapy No (have not and will not)	126 Participants n=138 Participants	56 Participants n=62 Participants	125 Participants n=123 Participants	307 Participants n=158 Participants
Receiving Hormone Therapy Currently receiving	241 Participants n=138 Participants	125 Participants n=62 Participants	203 Participants n=123 Participants	569 Participants n=158 Participants
Receiving Hormone Therapy Completed/ will start	32 Participants n=138 Participants	19 Participants n=62 Participants	31 Participants n=123 Participants	82 Participants n=158 Participants
Receiving Hormone Therapy Missing	13 Participants n=138 Participants	5 Participants n=62 Participants	15 Participants n=123 Participants	33 Participants n=158 Participants
Recurrence or Diagnosis of New Cancer At 3 months	5 participants n=138 Participants	0 participants n=62 Participants	5 participants n=123 Participants	10 participants n=158 Participants

PRIMARY outcome

Timeframe: Patients complete a survey within one week after their survivorship visit, and 6 months post visit.

Outcome measures

Outcome measures
Measure	Survivors in Consultative Specialized Survivorship Clinic Model: Within 1 Week Post-Visit n=393 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Consultative Specialized Survivorship Clinic (CSSC) with Direct Access. This model provides consultative survivorship care after treatment has ended through a single visit dedicated specifically to survivorship. The majority of Tier 1 Essential Elements, including the survivorship care plan (SCP), psychosocial care, health promotion services and symptom management, are provided through direct access during the survivorship visit. This model is typically led by a nurse practitioner (NP) or physician's assistant (PA) with specialized training.	Survivors in Consultative Specialized Survivorship Clinic Model: 6 Months Post-Visit n=323 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Consultative Specialized Survivorship Clinic (CSSC) with Direct Access. This model provides consultative survivorship care after treatment has ended through a single visit dedicated specifically to survivorship. The majority of Tier 1 Essential Elements, including the survivorship care plan (SCP), psychosocial care, health promotion services and symptom management, are provided through direct access during the survivorship visit. This model is typically led by a nurse practitioner (NP) or physician's assistant (PA) with specialized training.	Survivors in Longitudinal Specialized Survivorship Clinic Model: Within 1 Week Post-Visit n=187 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Longitudinal Specialized Survivorship Clinic (LSSC) with Direct Access. This model provides ongoing survivorship care through a series of survivorship-specific visits scheduled at predetermined intervals and as needed by the patient. The majority of Tier 1 essential elements are provided through direct access onsite rather than through a referral, including the SCP, surveillance for impacts of treatment, screenings for new cancers/recurrences, health promotion education, psychosocial care and symptom management. This model is typically led by an NP or a PA.	Survivors in Longitudinal Specialized Clinic Model: 6 Months Post-Visit n=159 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Longitudinal Specialized Survivorship Clinic (LSSC) with Direct Access. This model provides ongoing survivorship care through a series of survivorship-specific visits scheduled at predetermined intervals and as needed by the patient. The majority of Tier 1 essential elements are provided through direct access onsite rather than through a referral, including the SCP, surveillance for impacts of treatment, screenings for new cancers/recurrences, health promotion education, psychosocial care and symptom management. This model is typically led by an NP or a PA.	Survivors in Oncology Embedded Survivorship Clinic Model: Within 1 Week Post-Visit n=346 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Survivors in Oncology Embedded Survivorship Clinic Model: 6 Months Post-Visit n=295 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: End of Treatment-Baseline Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: 0-3 Months Post Visit Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: 3-6 Months Post Visit Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.
Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality Emotional and social support	33.1 percentage of participants	14.8 percentage of participants	30.7 percentage of participants	18.9 percentage of participants	20.2 percentage of participants	12.6 percentage of participants	—	—	—
Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality Information and Resources	75.5 percentage of participants	60.2 percentage of participants	73.9 percentage of participants	59.6 percentage of participants	65.9 percentage of participants	60.6 percentage of participants	—	—	—
Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality Empowered and Engaged Patients	59.0 percentage of participants	57.6 percentage of participants	60.7 percentage of participants	59.8 percentage of participants	50.5 percentage of participants	59.3 percentage of participants	—	—	—
Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality Supportive and Prepared Clinicians	59.9 percentage of participants	60.2 percentage of participants	58.7 percentage of participants	62.3 percentage of participants	56.4 percentage of participants	59.1 percentage of participants	—	—	—
Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality Open Patient-Clinician Communication	88.4 percentage of participants	86.3 percentage of participants	89.3 percentage of participants	88.4 percentage of participants	84.2 percentage of participants	87.5 percentage of participants	—	—	—
Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality Care Coordination and Transitions in Care	53.1 percentage of participants	57.3 percentage of participants	54.8 percentage of participants	59.1 percentage of participants	50.3 percentage of participants	57.5 percentage of participants	—	—	—
Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality Provision of Full Spectrum of Care	45.4 percentage of participants	41.4 percentage of participants	44.8 percentage of participants	45.9 percentage of participants	34.6 percentage of participants	39.7 percentage of participants	—	—	—
Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality Practical Life Support/ Health Insurance Issues	12 percentage of participants	8 percentage of participants	9.3 percentage of participants	13.2 percentage of participants	9.4 percentage of participants	14.8 percentage of participants	—	—	—
Percentage of Survivors Reporting "Yes Definitely" Across Items Within Each of 9 Factors Reflecting Survivorship Care Quality Medical Home	77.0 percentage of participants	82.3 percentage of participants	75.7 percentage of participants	84.0 percentage of participants	75.8 percentage of participants	82.9 percentage of participants	—	—	—

PRIMARY outcome

Timeframe: Patients complete a survey at baseline before their survivorship visit, and 6 months post visit.

Patient-reported quality of life concerns were measured using an index with 3 factors that represent physical concerns (consists of 8 metrics), social and emotional concerns (6 metrics), and practical concerns (2 metrics). The prevalence of top concerns in each domain were calculated. The top concerns were defined as those with \>40% prevalence at baseline across all three models. For physical concerns individuals received scores ranging from 0/8 to 8/8, for social/emotional concerns individuals were scored 0/6 to 6/6, and for practical concerns they were scored 0/2 to 2/2. The number presented is the average of those individual scores, converted into a percentage. The higher the number the more concerns participants reported

Outcome measures

Outcome measures
Measure	Survivors in Consultative Specialized Survivorship Clinic Model: Within 1 Week Post-Visit n=412 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Consultative Specialized Survivorship Clinic (CSSC) with Direct Access. This model provides consultative survivorship care after treatment has ended through a single visit dedicated specifically to survivorship. The majority of Tier 1 Essential Elements, including the survivorship care plan (SCP), psychosocial care, health promotion services and symptom management, are provided through direct access during the survivorship visit. This model is typically led by a nurse practitioner (NP) or physician's assistant (PA) with specialized training.	Survivors in Consultative Specialized Survivorship Clinic Model: 6 Months Post-Visit n=323 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Consultative Specialized Survivorship Clinic (CSSC) with Direct Access. This model provides consultative survivorship care after treatment has ended through a single visit dedicated specifically to survivorship. The majority of Tier 1 Essential Elements, including the survivorship care plan (SCP), psychosocial care, health promotion services and symptom management, are provided through direct access during the survivorship visit. This model is typically led by a nurse practitioner (NP) or physician's assistant (PA) with specialized training.	Survivors in Longitudinal Specialized Survivorship Clinic Model: Within 1 Week Post-Visit n=205 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Longitudinal Specialized Survivorship Clinic (LSSC) with Direct Access. This model provides ongoing survivorship care through a series of survivorship-specific visits scheduled at predetermined intervals and as needed by the patient. The majority of Tier 1 essential elements are provided through direct access onsite rather than through a referral, including the SCP, surveillance for impacts of treatment, screenings for new cancers/recurrences, health promotion education, psychosocial care and symptom management. This model is typically led by an NP or a PA.	Survivors in Longitudinal Specialized Clinic Model: 6 Months Post-Visit n=159 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Longitudinal Specialized Survivorship Clinic (LSSC) with Direct Access. This model provides ongoing survivorship care through a series of survivorship-specific visits scheduled at predetermined intervals and as needed by the patient. The majority of Tier 1 essential elements are provided through direct access onsite rather than through a referral, including the SCP, surveillance for impacts of treatment, screenings for new cancers/recurrences, health promotion education, psychosocial care and symptom management. This model is typically led by an NP or a PA.	Survivors in Oncology Embedded Survivorship Clinic Model: Within 1 Week Post-Visit n=374 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Survivors in Oncology Embedded Survivorship Clinic Model: 6 Months Post-Visit n=295 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: End of Treatment-Baseline Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: 0-3 Months Post Visit Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: 3-6 Months Post Visit Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.
Average Number of Quality of Life Top Concerns Reported Converted to a Percentage Top Social and Emotional Concerns	61.0 average number converted to a percentage Standard Deviation .36	58.1 average number converted to a percentage Standard Deviation .35	61.1 average number converted to a percentage Standard Deviation .37	63.6 average number converted to a percentage Standard Deviation .34	53.6 average number converted to a percentage Standard Deviation .36	54.2 average number converted to a percentage Standard Deviation .36	—	—	—
Average Number of Quality of Life Top Concerns Reported Converted to a Percentage Top Practical Concerns	42.7 average number converted to a percentage Standard Deviation .46	38.7 average number converted to a percentage Standard Deviation .45	41.5 average number converted to a percentage Standard Deviation .45	42.1 average number converted to a percentage Standard Deviation .47	44.5 average number converted to a percentage Standard Deviation .46	33.7 average number converted to a percentage Standard Deviation .45	—	—	—
Average Number of Quality of Life Top Concerns Reported Converted to a Percentage Top Physical Concerns	56.5 average number converted to a percentage Standard Deviation .30	54.5 average number converted to a percentage Standard Deviation .36	52.6 average number converted to a percentage Standard Deviation .30	58.3 average number converted to a percentage Standard Deviation .33	50.7 average number converted to a percentage Standard Deviation .31	53.1 average number converted to a percentage Standard Deviation .36	—	—	—

PRIMARY outcome

Timeframe: Patients complete a survey at baseline before their survivorship visit, within one week after their survivorship visit, 3 months post visit, and 6 months post visit.

Population: Participant population differs across rows because of lost to follow up in the study over time

Patient-reported self-efficacy was measured as the mean score of 8 metrics, reflecting how confident patients are that they can take care of different aspects of their health and health care after treatment has ended on a scale from 0 to 5, where 0=not at all confident and 5=totally confident.

Outcome measures

Outcome measures
Measure	Survivors in Consultative Specialized Survivorship Clinic Model: Within 1 Week Post-Visit n=412 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Consultative Specialized Survivorship Clinic (CSSC) with Direct Access. This model provides consultative survivorship care after treatment has ended through a single visit dedicated specifically to survivorship. The majority of Tier 1 Essential Elements, including the survivorship care plan (SCP), psychosocial care, health promotion services and symptom management, are provided through direct access during the survivorship visit. This model is typically led by a nurse practitioner (NP) or physician's assistant (PA) with specialized training.	Survivors in Consultative Specialized Survivorship Clinic Model: 6 Months Post-Visit n=205 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Consultative Specialized Survivorship Clinic (CSSC) with Direct Access. This model provides consultative survivorship care after treatment has ended through a single visit dedicated specifically to survivorship. The majority of Tier 1 Essential Elements, including the survivorship care plan (SCP), psychosocial care, health promotion services and symptom management, are provided through direct access during the survivorship visit. This model is typically led by a nurse practitioner (NP) or physician's assistant (PA) with specialized training.	Survivors in Longitudinal Specialized Survivorship Clinic Model: Within 1 Week Post-Visit n=374 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Longitudinal Specialized Survivorship Clinic (LSSC) with Direct Access. This model provides ongoing survivorship care through a series of survivorship-specific visits scheduled at predetermined intervals and as needed by the patient. The majority of Tier 1 essential elements are provided through direct access onsite rather than through a referral, including the SCP, surveillance for impacts of treatment, screenings for new cancers/recurrences, health promotion education, psychosocial care and symptom management. This model is typically led by an NP or a PA.	Survivors in Longitudinal Specialized Clinic Model: 6 Months Post-Visit Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Longitudinal Specialized Survivorship Clinic (LSSC) with Direct Access. This model provides ongoing survivorship care through a series of survivorship-specific visits scheduled at predetermined intervals and as needed by the patient. The majority of Tier 1 essential elements are provided through direct access onsite rather than through a referral, including the SCP, surveillance for impacts of treatment, screenings for new cancers/recurrences, health promotion education, psychosocial care and symptom management. This model is typically led by an NP or a PA.	Survivors in Oncology Embedded Survivorship Clinic Model: Within 1 Week Post-Visit Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Survivors in Oncology Embedded Survivorship Clinic Model: 6 Months Post-Visit Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: End of Treatment-Baseline Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: 0-3 Months Post Visit Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: 3-6 Months Post Visit Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.
Self- Efficacy Score Pre-Visit Baseline	3.94 Average Self-Efficacy Score (0-5 scale) Standard Deviation .78	3.89 Average Self-Efficacy Score (0-5 scale) Standard Deviation .78	4.03 Average Self-Efficacy Score (0-5 scale) Standard Deviation .73	—	—	—	—	—	—
Self- Efficacy Score 1 Week Post-Visit	4.26 Average Self-Efficacy Score (0-5 scale) Standard Deviation .59	4.25 Average Self-Efficacy Score (0-5 scale) Standard Deviation .59	4.26 Average Self-Efficacy Score (0-5 scale) Standard Deviation .59	—	—	—	—	—	—
Self- Efficacy Score 3 Month Post-Visit	4.02 Average Self-Efficacy Score (0-5 scale) Standard Deviation .74	4.03 Average Self-Efficacy Score (0-5 scale) Standard Deviation .73	4.11 Average Self-Efficacy Score (0-5 scale) Standard Deviation .71	—	—	—	—	—	—
Self- Efficacy Score 6 Month Post-Visit	4.09 Average Self-Efficacy Score (0-5 scale) Standard Deviation .75	4.07 Average Self-Efficacy Score (0-5 scale) Standard Deviation .68	4.20 Average Self-Efficacy Score (0-5 scale) Standard Deviation .69	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Patients complete a survey at baseline before their survivorship visit, 3 months post visit, and 6 months post visit.

Number of visits to health care providers at 3 different time points: end of treatment- baseline pre-survivorship visit, 0-3 months and 3-6 months post survivorship visit. The data presented are the mean (SD) number of visits to specific providers over time, by model.

Outcome measures

Outcome measures
Measure	Survivors in Consultative Specialized Survivorship Clinic Model: Within 1 Week Post-Visit n=412 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Consultative Specialized Survivorship Clinic (CSSC) with Direct Access. This model provides consultative survivorship care after treatment has ended through a single visit dedicated specifically to survivorship. The majority of Tier 1 Essential Elements, including the survivorship care plan (SCP), psychosocial care, health promotion services and symptom management, are provided through direct access during the survivorship visit. This model is typically led by a nurse practitioner (NP) or physician's assistant (PA) with specialized training.	Survivors in Consultative Specialized Survivorship Clinic Model: 6 Months Post-Visit n=365 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Consultative Specialized Survivorship Clinic (CSSC) with Direct Access. This model provides consultative survivorship care after treatment has ended through a single visit dedicated specifically to survivorship. The majority of Tier 1 Essential Elements, including the survivorship care plan (SCP), psychosocial care, health promotion services and symptom management, are provided through direct access during the survivorship visit. This model is typically led by a nurse practitioner (NP) or physician's assistant (PA) with specialized training.	Survivors in Longitudinal Specialized Survivorship Clinic Model: Within 1 Week Post-Visit n=323 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Longitudinal Specialized Survivorship Clinic (LSSC) with Direct Access. This model provides ongoing survivorship care through a series of survivorship-specific visits scheduled at predetermined intervals and as needed by the patient. The majority of Tier 1 essential elements are provided through direct access onsite rather than through a referral, including the SCP, surveillance for impacts of treatment, screenings for new cancers/recurrences, health promotion education, psychosocial care and symptom management. This model is typically led by an NP or a PA.	Survivors in Longitudinal Specialized Clinic Model: 6 Months Post-Visit n=205 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through a Longitudinal Specialized Survivorship Clinic (LSSC) with Direct Access. This model provides ongoing survivorship care through a series of survivorship-specific visits scheduled at predetermined intervals and as needed by the patient. The majority of Tier 1 essential elements are provided through direct access onsite rather than through a referral, including the SCP, surveillance for impacts of treatment, screenings for new cancers/recurrences, health promotion education, psychosocial care and symptom management. This model is typically led by an NP or a PA.	Survivors in Oncology Embedded Survivorship Clinic Model: Within 1 Week Post-Visit n=175 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Survivors in Oncology Embedded Survivorship Clinic Model: 6 Months Post-Visit n=159 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: End of Treatment-Baseline n=374 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: 0-3 Months Post Visit n=328 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.	Oncology Embedded Survivorship Clinic Model: 3-6 Months Post Visit n=295 Participants Non-metastatic breast, prostate and colorectal cancer survivors receiving survivorship care through Oncology Embedded Survivorship Clinics (OESC) with Varied Access. This model provides survivorship care as part of standard post-treatment oncology follow-up care. Because this model integrates survivorship with standard follow-up care, it is considered a longitudinal model, though institutions also report survivorship is not always provided systematically as in Model 2 but rather on an as needed basis at the request of the patient. Institutions with the Embedded model are more likely to use referrals to deliver some of the key survivorship services than either of the other two models. Survivorship care in this model is typically provided by the treating oncologist often with support from an NP/PA, patient navigator or social worker.
Frequency of Visit Primary Care Physician	.71 mean number of visits Standard Deviation 1.3	1.0 mean number of visits Standard Deviation 1.2	.91 mean number of visits Standard Deviation 1.3	.77 mean number of visits Standard Deviation 1.4	.90 mean number of visits Standard Deviation 1.0	.76 mean number of visits Standard Deviation .9	.78 mean number of visits Standard Deviation 1.4	1.1 mean number of visits Standard Deviation 1.3	.88 mean number of visits Standard Deviation 1.1
Frequency of Visit Oncology	1.59 mean number of visits Standard Deviation 1.8	1.15 mean number of visits Standard Deviation 1.0	.97 mean number of visits Standard Deviation 1.0	2.22 mean number of visits Standard Deviation 2.2	1.31 mean number of visits Standard Deviation 1.4	1.09 mean number of visits Standard Deviation 1.3	1.77 mean number of visits Standard Deviation 2.1	1.32 mean number of visits Standard Deviation 1.2	1.09 mean number of visits Standard Deviation 1.1
Frequency of Visit Hospital	.49 mean number of visits Standard Deviation 1.5	.51 mean number of visits Standard Deviation 1.5	.41 mean number of visits Standard Deviation 1.1	.22 mean number of visits Standard Deviation .71	.34 mean number of visits Standard Deviation 1.1	.27 mean number of visits Standard Deviation .68	.54 mean number of visits Standard Deviation 1.8	.55 mean number of visits Standard Deviation 1.2	.58 mean number of visits Standard Deviation 1.2
Frequency of Visit Other Specialists	1.6 mean number of visits Standard Deviation 2.7	1.94 mean number of visits Standard Deviation 2.9	1.33 mean number of visits Standard Deviation 2.5	2.0 mean number of visits Standard Deviation 3.5	2.14 mean number of visits Standard Deviation 3.2	1.71 mean number of visits Standard Deviation 2.9	1.45 mean number of visits Standard Deviation 2.5	1.73 mean number of visits Standard Deviation 2.7	1.13 mean number of visits Standard Deviation 2.0

Adverse Events

Cancer Survivors in Consultative Specialized Survivorship Clinic Model

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Cancer Survivors in Longitudinal Specialized Survivorship Clinic Model

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Cancer Survivors in Oncology Embedded Survivorship Clinic Model

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

K. Holly Mead

GW University

Phone: 202-994-8615

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place